Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Department of Urology, People's Hospital of Deyang City, Deyang 618000, China.
Asian J Androl. 2022 Mar-Apr;24(2):180-185. doi: 10.4103/aja202188.
Neoadjuvant chemotherapy (NAC) has shown promising results in patients with locally advanced penile cancer. However, no consensus exists on its applications for locally advanced penile cancer. Thus, it is unclear which kind of chemotherapy regimen is the best choice. Consequently, a systematic search of PubMed, Web of Science, and EMBASE was performed in March 2021 to assess the efficacy and safety of NAC for the treatment of patients with locally advanced penile cancer. The Newcastle-Ottawa Scale was used to assess the risk of bias in each study. This study synthesized 14 published studies. The study revealed that patients who achieved an objective response to NAC obtained a better survival outcome compared with those who did not achieve an objective response. In addition, the objective response rates (ORRs) and pathological complete response (pCR) rates were 0.57 and 0.11, respectively. The incidence of grade ≥3 toxicity was 0.36. Subgroup analysis found that the ORR and pCR of the taxane-platinum (TP) regimen group performed better than those of the nontaxane-platinum (NTP) regimen group (0.57 vs 0.54 and 0.14 vs 0.07, respectively). Moreover, the TP regimen group had more frequent toxicity than the NTP regimen group (0.41 vs 0.26). However, further studies were warranted to confirm the findings.
新辅助化疗（NAC）在局部晚期阴茎癌患者中显示出良好的效果。然而，对于局部晚期阴茎癌的应用尚无共识。因此，不清楚哪种化疗方案是最佳选择。因此，我们于 2021 年 3 月对 PubMed、Web of Science 和 EMBASE 进行了系统检索，以评估 NAC 治疗局部晚期阴茎癌患者的疗效和安全性。使用纽卡斯尔-渥太华量表（Newcastle-Ottawa Scale）评估每个研究的偏倚风险。本研究综合了 14 项已发表的研究。研究结果表明，与未达到客观缓解的患者相比，对 NAC 有客观缓解的患者有更好的生存结局。此外，客观缓解率（ORR）和病理完全缓解（pCR）率分别为 0.57 和 0.11，≥3 级毒性的发生率为 0.36。亚组分析发现，紫杉烷-铂类（TP）方案组的 ORR 和 pCR 优于非紫杉烷-铂类（NTP）方案组（0.57 比 0.54 和 0.14 比 0.07）。此外，TP 方案组的毒性发生率高于 NTP 方案组（0.41 比 0.26）。然而，需要进一步的研究来证实这些发现。
